LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Danaher Partners with Healthcare AI Company Innovaccer on Novel Digital and Diagnostic Solutions

By LabMedica International staff writers
Posted on 10 Jan 2025
Image: The investment is in line with Danaher’s aim to accelerate the transition to precision medicine with AI-enabled diagnostics
Image: The investment is in line with Danaher’s aim to accelerate the transition to precision medicine with AI-enabled diagnostics

Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation (Washington, DC, USA), has formed an investment partnership with healthcare artificial intelligence (AI) company Innovaccer Inc. (San Francisco, CA, USA) with the aim of improving patient outcomes and experience through novel digital and diagnostic solutions. The investment aligns with Danaher's mission to accelerate the transition to precision medicine with AI-enabled diagnostics.

Innovaccer has developed a suite of software solutions designed to create a unified patient record to identify gaps in care and patients at risk, as well as appropriate interventions to improve patient outcomes. As part of the investment partnership, Danaher, along with Innovaccer and its network of healthcare systems, aims to accelerate the adoption of precision diagnostics both by clinicians and population health teams, facilitating value-based care.

"Patients are at the center of everything we do at Danaher. We believe our investment partnership with Innovaccer will empower patients and speed the transition to more personalized, value-based medicine by providing healthcare providers with the data and analytics needed to drive meaningful clinical insights, more quickly, and at the point of need," said Julie Sawyer Montgomery, Executive Vice President, Danaher Corporation.

"Danaher is committed to ethically using AI to develop and deliver better diagnostics to help doctors treat their patients with the right medicine in the right dose at the right time," said Murali Venkatesan, Head of Danaher Ventures, Americas & Europe and Vice President of Science, Technology and Innovation, Danaher Corporation. "We're excited to connect our innovation ecosystem with Innovaccer's to enable this healthcare transformation."

"At Innovaccer, we are on a mission to improve health outcomes through our data platform and AI capabilities," said Abhinav Shashank, cofounder and CEO of Innovaccer. "We believe that partnering with Danaher will accelerate our efforts to advance diagnostic and clinical AI solutions."

Related Links:
Danaher Corporation
Innovaccer Inc.

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Human Estradiol Assay
Human Estradiol CLIA Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more